Resolving Uncertainty in Alagille Syndrome Diagnostics
解决阿拉吉尔综合征诊断中的不确定性
基本信息
- 批准号:10734881
- 负责人:
- 金额:$ 58.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2028-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccountingAffectAlagille SyndromeAtlasesBenignBiological AssayCalibrationCell LineCellsChildhoodClassificationClinVarClinicalComplexDNADataDetectionDevelopmentDiagnosisDiagnosticDiseaseEtiologyEvaluationExonsEyeFaceFaciesFormalinFutureGene ExpressionGene Expression ProfileGene Expression ProfilingGenesGeneticGenetic DiseasesGenetic VariationGenomic medicineGenomicsGenotypeHeartHigh PrevalenceIndividualKidneyKnowledgeLibrariesLigandsLiverLiver diseasesManaged CareMeasuresMembraneMendelian disorderMethodologyMethodsMissense MutationModelingMolecularMutationNotch Signaling PathwayNucleotidesParaffin EmbeddingPathogenicityPatient CarePatientsPersonsPhenotypePositioning AttributePropertyProtein TruncationProteinsProteomicsReceptor SignalingReporterReportingResolutionSamplingSeriesSeverity of illnessSignal TransductionSiteSystemTechniquesTestingTherapeuticTissue SampleUncertaintyValidationVariantWorkautosomeclinical diagnosticsdesigndisorder controlexperimental studyglycosylationhigh throughput screeningimprovedinnovationliver transplantationloss of functionmultiplex assaymutantnotch proteinprotein functionreceptorsample fixationspine bone structuretooltranscriptomicsvariant of unknown significance
项目摘要
PROJECT SUMMARY/ABSTRACT
Uncertainty in genomic diagnostics creates a barrier to realizing the full potential of genomic medicine.
Uncertainty is evident in: 1) our inability to determine if some DNA variants are pathogenic or benign and 2) our
inability to predict to what extent a person with a disease-causing variant will be affected, due to variable
expressivity. This proposal will study both phenomena for the autosomal dominant disorder Alagille syndrome,
caused by mutations in one of two genes in the Notch signaling pathway, the ligand JAGGED1 (JAG1) or the
receptor, NOTCH2. Alagille syndrome is characterized by pediatric liver, heart, vertebral, renal, ocular, and
facial anomalies with highly variable expressivity. The mechanism of disease for JAG1-related Alagille
syndrome is haploinsufficiency whereas the mechanism for NOTCH2-related Alagille syndrome is less clear,
with fewer reported variants, less functional characterization, and a higher prevalence of missense variants
(>50%). Missense variants are difficult to classify, often requiring functional validation to support or reject
pathogenicity. In Alagille syndrome, functional characterization has been carried out for only 19/125 reported
missense mutations, thus, despite a high detection rate, the diagnostic rate is lower due to this uncertainty.
We propose to resolve uncertainty in the diagnostics of Alagille syndrome using assays designed to
characterize the pathogenicity of JAG1 and NOTCH2 missense variants and analysis of gene expression data
from patient liver samples to identify gene expression signatures that can be used for genotype-phenotype
evaluations. In Aim 1, we will design a Site Saturation Variant Library of all possible nucleotide permutations at
each nucleotide position across a region with high missense variant uncertainty in the JAG1 C-terminus and
test this library by developing a Multiplexed Assay for Variant Effects (MAVEs) that will measure cellular
localization of JAG1 as a readout of protein function. In Aim 2, we will use FFPE liver tissue samples to
analyze gene expression differences between Alagille syndrome patients and controls, as well as between
Alagille syndrome patients with mild versus severe liver disease. In Aim 3, we will study the molecular basis of
NOTCH2 variants through functional, expression, and enzymatic assays using mutant cell lines. We
hypothesize that these proposed assays will identify a high-throughput method to test missense pathogenicity
(Aim 1), identify gene expression differences between Alagille syndrome patients and controls as well as gene
expression signatures that are different between Alagille syndrome patients with mild versus severe liver
disease (Aim 2), and determine the mechanism by which NOTCH2 variants cause Alagille syndrome through
functional analysis (Aim 3). Ultimately, these data will improve variant analysis for Alagille syndrome,
improve our understanding of the molecular basis of liver disease in Alagille syndrome, and establish
a framework for scalable classification of missense variants, delivering diagnostic information that can
directly help clinicians.
项目总结/摘要
基因组诊断的不确定性对实现基因组医学的全部潜力造成了障碍。
不确定性是显而易见的:1)我们无法确定一些DNA变异是致病的还是良性的,2)我们的
无法预测在何种程度上一个人与致病变异将受到影响,由于变量
表现力本提案将研究常染色体显性遗传病Alagille综合征的两种现象,
由Notch信号通路中的两个基因之一突变引起,即配体JAGGED 1(JAG 1)或
受体,NOTCH 2。Alagille综合征的特征在于儿科肝脏、心脏、脊椎、肾脏、眼部和
表情多变的面部异常JAG 1相关Alagille的发病机制
综合征是单倍功能不全,而NOTCH 2相关的Alagille综合征的机制尚不清楚,
报告的变异较少,功能特征较少,错义变异的发生率较高
(>50%)。错义变体很难分类,通常需要功能验证来支持或拒绝
致病性在Alagille综合征中,仅对19/125例报告的患者进行了功能表征
因此,尽管检测率高,但由于这种不确定性,诊断率较低。
我们建议使用设计的测定来解决Alagille综合征诊断中的不确定性,
表征JAG 1和NOTCH 2错义变体的致病性并分析基因表达数据
以鉴定可用于基因型-表型分析的基因表达特征
评价。在目标1中,我们将设计所有可能的核苷酸排列的位点饱和变体文库,
在JAG 1 C-末端具有高错义变体不确定性的区域上的每个核苷酸位置,
通过开发一种用于变异效应的多重测定(MAVE)来测试该文库,
定位JAG 1作为蛋白质功能的读数。在目标2中,我们将使用FFPE肝组织样本,
分析Alagille综合征患者和对照之间的基因表达差异,以及
轻度与重度肝病的Alagille综合征患者。在目标3中,我们将研究
通过使用突变细胞系的功能、表达和酶促测定的NOTCH 2变体。我们
假设这些提出的测定法将鉴定出高通量方法来测试错义致病性
(Aim 1)确定Alagille综合征患者和对照之间的基因表达差异以及基因表达差异。
Alagille综合征轻度与重度肝病患者之间的不同表达特征
疾病(目的2),并确定NOTCH 2变异体通过以下途径引起Alagille综合征的机制:
功能分析(目标3)。最终,这些数据将改善Alagille综合征的变异分析,
提高我们对Alagille综合征肝病分子基础的理解,并建立
错义变体的可扩展分类框架,提供诊断信息,
直接帮助临床医生。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nancy Bettina Spinner其他文献
Nancy Bettina Spinner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nancy Bettina Spinner', 18)}}的其他基金
Training Program in the Genetic Basis of Pediatric Gastrointestinal Disorders
儿科胃肠道疾病遗传基础培训计划
- 批准号:
8883521 - 财政年份:2014
- 资助金额:
$ 58.15万 - 项目类别:
Training Program in the Genetic Basis of Pediatric Gastrointestinal Disorders
儿科胃肠道疾病遗传基础培训计划
- 批准号:
8666845 - 财政年份:2014
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
7883529 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
7661203 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
8502652 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
8097573 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
8306850 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
Genetic Modifiers of Liver Disease Severity in Alagille Syndrome
阿拉吉尔综合征肝病严重程度的基因修饰
- 批准号:
8090799 - 财政年份:2009
- 资助金额:
$ 58.15万 - 项目类别:
NOTCH SIGNALING PATHWAY LIGANDS IN CARDIOVASCULAR DISEASE
心血管疾病中的 NOTCH 信号通路配体
- 批准号:
6565108 - 财政年份:2002
- 资助金额:
$ 58.15万 - 项目类别:
NOTCH SIGNALING PATHWAY LIGANDS IN CARDIOVASCULAR DISEASE
心血管疾病中的 NOTCH 信号通路配体
- 批准号:
6302546 - 财政年份:2000
- 资助金额:
$ 58.15万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 58.15万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 58.15万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 58.15万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 58.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists